Results 161 to 170 of about 17,166 (251)

Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis. [PDF]

Respir Res
Gramegna A, Cimino G, Cipolli M, Gandini G, Calderazzo MA, Profiti A, Piedepalumbo F, Blasi F.   +7 more
europepmc   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis. [PDF]

Pediatr Pulmonol
Trost SU, Harindhanavudhi T, Wang Q, Ankireddypalli A, Simrah A, Avula S, Moheet A.   +6 more
europepmc   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor Supports Treatment for CF with ΔI1023-V1024-CFTR. [PDF]

Int J Mol Sci
Huang Y, Gonzales Cordova JM, Penrod S, Bendy LL, Cheng PC, Sanders DB, Davis MD, Gaston B, Chmiel JF.   +8 more
europepmc   +1 more source

Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. [PDF]

Ann Am Thorac Soc
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM, PROMISE Study Group .   +15 more
europepmc   +1 more source

Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor Therapy. [PDF]

Am J Respir Crit Care Med
Piehler L, Thalemann R, Lehmann C, Stahl M, Mall MA, Graeber SY.   +5 more
europepmc   +1 more source

Large variations in total and allele-specific transcript expression in a disease mutation-independent manner. [PDF]

Sci Rep
Freyberg M, Bewig M, Bampi GB, Manfredi C, Joshi D, Rauscher R, Hong JS, Große-Onnebrink J, Sutharsan S, Stehling F, Bobis I, Ballmann M, Sorscher EJ, Ignatova Z.   +13 more
europepmc   +1 more source

The Changing Transplant Landscape in the Era of Elexacaftor/Tezacaftor/Ivacaftor: A Word of Caution. [PDF]

Clin Transplant
Semenchuk J, Tuff-Gordon E, Ma X, Sykes J, Cheng SY, Aversa M, Chaparro C, Tullis E, Stephenson AL.   +8 more
europepmc   +1 more source

Modulation of host inflammatory pathways by <i>Pseudomonas aeruginosa</i> extracellular vesicles in cystic fibrosis: impact of pulmonary exacerbation and elexacaftor-tezacaftor-ivacaftor treatment. [PDF]

Front Immunol
Said M, Burrell A, Harmon B, Krohmaly KI, Mazur M, Solomon GM, Hahn A.   +6 more
europepmc   +1 more source